Bayer stock jumped on Monday after the German healthcare company said a late-stage stroke drug trial achieved its goals.

Bayer's successful trial comes after it previously halted a phase 3 clinical trial testing the effectiveness of the same experimental drug for stroke and systemic embolism prevention in 2023. At the ...

Shares in Bayer jumped more than 8% on Monday after initial clinical trial results turned around the fortunes of a key ...

Bayer AG said an experimental stroke-prevention drug showed positive results in a late-stage clinical study, a boost for the ...

Bayer shares surge after its asundexian stroke drug shows positive Phase III results, offering a key boost to its pipeline ...

Investing.com -- Bayer’s (ETR:BAYGN) experimental stroke drug could generate €3 billion in annual sales after successful trial results that Goldman Sachs analyst James Quigley called "transformational ...

The Chinese e-commerce leader said its Qwen artificial-intelligence app drew more than 10 million downloads i ...

Bayer has let go of about 13,500 employees, including around 5,000 managers, since implementing a new operating model in ...

The nod brings Bayer face-to-face in the market with Boehringer Ingelheim and AstraZeneca, each of which has its own HER2 ...

Bayer has built a home for Chinese biopharma companies. Located in Beijing, the Bayer E-Town Open Innovation Center will ...